MedPath

ViiV Healthcare BV

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://viivhealthcare.com/nl-nl

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

59

CIMA_AEMPS:29
NMPA:15
EMA:15

Drug Approvals

Cabotegravir Injection

Product Name
万凯锐
Approval Number
国药准字HJ20230093
Approval Date
Jul 11, 2023
NMPA

Cabotegravir Sodium Tablets

Product Name
万凯锐
Approval Number
国药准字HJ20230094
Approval Date
Jul 11, 2023
NMPA

Cabotegravir Injection

Product Name
万凯锐
Approval Number
国药准字HJ20230092
Approval Date
Jul 11, 2023
NMPA

Dolutegravir Sodium Dispersible Tablets

Product Name
多替拉韦钠分散片
Approval Number
国药准字HJ20230060
Approval Date
May 29, 2023
NMPA

Dolutegravir Sodium and Rilpivirine Hydrochloride Tablets

Product Name
多替拉韦利匹韦林片
Approval Number
国药准字HJ20220081
Approval Date
Oct 18, 2022
NMPA

Lamivudine Tablets

Product Name
益平维
Approval Number
国药准字HJ20171228
Approval Date
Aug 31, 2022
NMPA

Dolutegravir Sodium, Abacavir Sulfate and Lamivudine Tablets

Product Name
绥美凯
Approval Number
国药准字HJ20170345
Approval Date
May 23, 2022
NMPA

Abacavir Sulfate Tablets

Product Name
赛进
Approval Number
国药准字HJ20160636
Approval Date
Oct 22, 2021
NMPA

Abacavir Sulfate Oral Solution

Product Name
赛进
Approval Number
国药准字HJ20150202
Approval Date
Jun 8, 2021
NMPA

Lamivudine Oral Solution

Product Name
益平维
Approval Number
国药准字HJ20140181
Approval Date
May 12, 2021
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.